|02-15-2019 04:34 PM CET - Business, Economy, Finances, Banking & Insurance||
Stroke Disorder and Treatment Market 2019 Key Country Analysis: AstraZeneca, Pfizer, Bayer Pharma AG, Daiichi Sankyo, Novartis AG and other
Press release from: Market Research Future
The Global Stroke Disorder And Treatment Market is presumed to demonstrate a healthy CAGR during the forecast period (2016-2022) owing to the rising high blood pressure patients, asserts Market Research Future (MRFR). Stroke is referred to as the condition which occurs when clot is formed in the artery and oxygen supply is cut off. Brain cells thus get deprived of oxygen and start to die. Heart and brain strokes can strike any moment and can be fatal. Stroke is considered as one of the leading causes of death across the world with higher prevalence in the geriatric population.
Get Sample Copy @ www.marketresearchfuture.com/sample_request/1651
Drivers and Constraints Impacting the Market
With increasing consumption of alcohol and diabetic patients, the global stroke disorder and treatment market is likely to flourish. Also, the increasing prevalence of cardiovascular diseases is highly influencing the market across the globe. Brain problems and heart problems are considered as the most dangerous medical issues across the world with expensive medication and treatments. Thus, the market offering treatment for it is lucrative. The market is further accelerated by the huge patient pool along with rising geriatric population across the globe. Moreover, atrial fibrillation, hypertension, and coronary heart diseases are contributing to the growth of the market.
On the flip side, high cost of treatment adversely affects the growth of the market. Moreover, the lack of transparent reimbursement scenario is also likely to dampen the stroke disorder and treatment market during the assessment period.
Global Stroke Disorder and Treatment Market: Segmental Analysis
The global stroke disorder and treatment market has been segmented on the basis of type, medicine, treatment, and region.
By mode of type, the global stroke disorder and treatment market has been segmented into ischemic stroke and hemorrhagic strokes. Among these, the weakened blood vessel leakage is referred to as hemorrhagic stroke. Ischemic stroke generally occurs due to an obstruction within a blood vessel which supplies blood to the brain.
By mode of medicine, the global stroke disorder and treatment market has been segmented into anticoagulants/antiplatelet, anti-hypertensive.
By mode of treatment, the global stroke disorder and treatment market has been segmented into tissue plasminogen activator (TPA), carotid endarterectomy, surgical treatment, endovascular procedures, and others. TPA is referred to as an enzyme involved in the breakdown of blood clots and dissolves them. It is a less invasive procedure and is used for treating problems affecting the blood vessels like aneurysm.
The prominent players operating the global stroke disorder and treatment market are AstraZeneca (U.K), Bayer Pharma AG (Germany), Novartis AG (Switzerland), Daiichi Sankyo (Japan), and Pfizer (U.S).
Geographically, the stroke disorder and treatment market span across regions namely, Europe, North America, Asia Pacific, and Rest-of-the-World.
Among these, the North America region is presumed to dominate the stroke diagnostics and therapeutics market and is likely to maintain its dominance. The growth is attributed to the rising awareness among the population regarding the symptoms of stroke followed by the several harmful effects associated with high glucose level in blood. With technological advancements and high-end research, and rising public interest, the demand for stroke disorder and treatment is likely to trigger in the coming years. Moreover, encouraging healthcare infrastructure and higher healthcare expenditure are some of the major factors contributing to the growth of the stroke disorder and treatment market.
European holds the second-largest position with high diabetic population. Moreover, the growing percentage of diabetes mellitus population is directly proportionate to the associated risk of stroke in individuals, thereby contributing to the market growth during the assessment period. Additionally, technological advancements and healthcare research are further influencing the market growth.
CERENOVUS business has recently launched the single largest global registry, the EXCELLENT Registry, in order to collect and analyze stroke-inducing blood clots removed from the brain with its EMBOTRAP II Revascularization Device. The EXCELLENT Registry is likely to enroll up to 1000 ischemic stroke patients in as many as 50 clinical sites in Europe and the United States.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ www.marketresearchfuture.com/reports/stroke-disorder-trea...
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Phone: +1 646 845 9312
This release was published on openPR.
News-ID: 1592962 • Views: 285More releases